Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BJ Wholesale Club Holdings releases latest performance guidance, expects same-store sales to achieve annual year-on-year growth of 2% to 3% by fiscal year 2026, excluding gasoline sales volatility.

BJ Wholesale Club Holdings releases latest performance guidance, expects same-store sales to achieve annual year-on-year growth of 2% to 3% by fiscal year 2026, excluding gasoline sales volatility.

老虎证券老虎证券2026/03/05 11:56
Show original
This expectation highlights the membership-based warehouse retailer's confidence in the growth momentum of its core business, while also reflecting management's optimistic outlook for organic growth over the next three years. Compared to traditional retail indicators, same-store sales excluding fuel sales more accurately reflect store operational efficiency and member consumption stickiness. Analysts point out that this target range aligns with the steady growth expectations of industry leaders under the current macroeconomic environment, and also demonstrates the sustained momentum brought by the company through optimizing product structure and enhancing member value.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Halozyme shares rise after winning a case against Merck's injectable Keytruda in a Dutch court

October 7 – Halozyme (HALO.O) shares rose 1.4% pre-market to $111.24. Halozyme announced it had obtained an injunction from a Dutch court (link), prohibiting Merck MRK.N from manufacturing, selling, and importing subcutaneous Keytruda in eight European markets. The court determined that Merck had infringed Halozyme’s EP622 patent and rejected Merck’s claims that the patent was invalid. Halozyme stated that patients will still have access to the intravenous version of Keytruda, which is not affected by the injunction. As of the close of the previous trading day, HALO shares have risen 62% this year. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to possible errors or missing context in automated translations, Reuters does not guarantee the accuracy of such translated texts, which are provided for readers’ convenience only. Reuters assumes no liability for any damages or losses caused by use of the automated translation function.)

路透社•2026/10/07 13:31

BUZZ-KeyBanc upgrades Corteva rating to "Overweight"; stock price rises

On October 7, KeyBanc upgraded the rating of agricultural technology company Corteva Inc (CTVA.N) from "Sector Weight" to "Overweight." CTVA rose 1.6% in pre-market trading to $14.1. The brokerage pointed out that new product launches, cost reductions, and improvements in farmers' economic conditions will be strong growth drivers for 2028-2029. The company’s ample cash reserves enable it to flexibly fund growth initiatives, stock buybacks, and potential acquisitions. Out of 23 brokerages, 16 have given the stock a "Buy" or higher rating, and 7 have rated it "Hold." The median target price is $18. As of the previous trading day's close, the stock had gained 38.3% year to date.

路透社•2026/10/07 13:27

Elon Musk personally defines Terafab: TSMC can at most "sublease a portion," operation is out of the question.

Musk clarified that Terafab will be independently constructed and operated, with TSMC possibly subleasing part of the site; Intel will be involved in technology development and will supply Tesla and SpaceX AI.

智通财经•2026/10/07 13:18